Open Orphan Takeover Of hVIVO Now Wholly Unconditional
Open Orphan Takeover Of hVIVO Now Wholly Unconditional
Read moreMon, 01st Feb 2021 13:20
Open Orphan Takeover Of hVIVO Now Wholly Unconditional
Read moreOpen Orphan Readmitted To AIM Following Reverse Takeover Of hVIVO
Read moreOpen Orphan To Mount Compulsory Buyout To Get hVIVO Deal Over Line
Read moreUPDATE: Open Orphan To Relist On AIM Following hVIVO All-Share Merger
Read moreOpen Orphan To Relist On AIM Following hVIVO All-Share Merger
Read more(Sharecast News) - Drug consulting services platform Open Orphan has won a new three-year contract with an unnamed German pharmaceutical company.
Read moreOpen Orphan Meets Acceptance Condition For Merger With hVIVO
Read moreUK Shareholder Meetings Calendar - Next 7 Days
Read more(Sharecast News) - Europe-focussed rare and orphan drug consulting service provider Open Orphan announced the signing of a contract with SFA Therapeutics, a biopharmaceutical company based in Pennsylvania, on Wednesday.
Read moreOpen Orphan Unit To Assist SFA Therapeutics In Filing Drug Application
Read more(Sharecast News) - Open Orphan, the rare and orphan drug services company, has agreed the takeover of hVIVO by means of an all-share reverse take-over at a 33.8% premium.
Read moreAIM-Listed Firms Open Orphan And hVIVO Set For Tie-Up
Read moreOpen Orphan Signs Five Companies For Genomic Health DataBANK Platform
Read moreOpen Orphan Teams With Carna For Human Clinical Pharmacology Trial
Read more(Sharecast News) - Rare and orphan drug consulting services provider Open Orphan announced the signing of a contract with Carna Bioscience for a first-in-human clinical pharmacology trial, it announced on Monday.
Read more